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Abstract Factor VIIa is a vitamin K-dependent enzyme whose 
~-carboxyglutamic a id (Gla)-containing domain is important for 
calcium ion-dependent binding to the cofactor tissue factor and 
membrane surfaces. This domain contains 10 Gla residues, the 
individual roles and importance of which are not known. 
Comparisons with the homologous protein C, factor IX and 
prothrombin may provide functional information on the first nine 
Gla residues, whereas no data can be extrapolated to Gla-35 in 
factor VIIa. Therefore, the effects of posttranslational y- 
carboxylation and site-directed mutagenesis of Glu-35 were 
investigated. Mutations to Asp, Gin or Val all lead to a lower 
affinity for tissue factor by decreasing the rate of association, in 
the case of the Val mutant by a factor of 200, as measured by 
surface plasmon resonance. In contrast, Gin or Gla side chains at 
position 35 appear to fulfil the functional roles equally well. 
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1. Introduction 
Coagulation factor VII (fVII) belongs to the family of vi- 
tamin K-dependent plasma proteins characterized by their 
posttranslationally y-carboxylated Glu residues located in 
well-conserved positions [1]. The N-terminal domain, encoded 
on a separate xon, contains the first 37 amino acid residues 
including all 10 y-carboxyglutamic a id (Gla) residues [2]. This 
so-called Gla domain binds seven Ca r+ ions [3,4], an event 
mediated by the Gla residues, and thereby attains a mem- 
brane-interactive ability through the exposure of hydrophobic 
side chains [4,5]. Studies of the roles of the individual Gla 
residues in factor IX [6], protein C [7-10] and prothrombin 
[11], all of  which are homologous to fVII, have been con- 
ducted. They demonstrated functional differences between 
various Gla residues but similar, although with a few differ- 
ences, patterns for the three proteins and this presumably also 
applies to fVII. Thus, the anticipated roles of the first 9 Gla 
residues in fVII regarding properties common to all vitamin 
K-dependent plasma proteins, such as basic structure main- 
tenance, Ca 2+ and phospholipid binding, can be inferred. 
However, protein C and prothrombin have no Gla residue 
corresponding to Gla-35 in fVII and the corresponding factor 
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IX mutant was not included in that study. In addition, residue 
35 was poorly ordered in the crystal structure of the complex 
between fVIIa and tissue factor (TF) [4]. Therefore, it was of 
interest o us to investigate the consequences of mutating this 
residue in fVII. In addition, the production of factors VII and 
IX in mammalian cell cultures is fraught by the problem of 
partial y-carboxylation of the most C-terminal Gla residues 
[12,13] and we also wanted to determine the effects of this 
specific modification of Glu-35 in fVlI. 
2. Materials and methods 
2.1. Proteins, materials and standard methods 
Recombinant fVIla was purified according to Thim et al. [12]. The 
y35 and E35 isoforms of fVIIa were separated by ion-exchange chro- 
matography on a NucleoPac PA-100 column using a ff4).85 M linear 
gradient of ammonium acetate in 10 mM Tris, 10 mM Bis-Tris pro- 
pane, pH 9.2. The two forms were identified by mass spectrometry 
and N-terminal amino acid sequencing (with positive identification of 
Gla) of peptic and tryptic peptides (manuscript in preparation). The 
ELISA employing the monoclonal antibodies F1A2 and F6A4 was 
carried out as described [14]. SDS-PAGE was run according to 
Laemmli [15]. 
Materials for cell culturing were from Gibco. Taq polymerase was 
from Perkin-Elmer and Pwo polymerase was from Boehringer Mann- 
heim. 
2.2. fV l l  cDNA constructions 
For cDNA constructions the following PCR primers were used: 
1. (A) AAC GGA TCC ACC ATG GTC TCC CAG GCC CTC 
AGG 
2. (B) ACG GAA TTC ACT AGT CTA GGG AAA TGG GGC 
TCG CAG GA 
3. (C) CGT CCT GTC CGC GTC CTT GAA 
4. (D) TTC AAG GAC GCG GAC AGG ACG 
5. (E) CGT CCT CTG CGC GTC CTT GAA 
6. (F) TTC AAG GAC GCG CAG AGG ACG 
7. (G) CGT CCT AAC CGC GTC CTT GAA 
8. (H) TTC AAG GAC GCG GTT AGG ACG 
A wild-type fVII cDNA for expression was prepared by PCR with 
Taq polymerase using primer A as 5' primer, primer B as 3' primer 
and the human cDNA [16] as a template, This adds a BamHI site to 
the 5' end and an EcoRI site followed by an internal SpeI site to the 
3' end. At the same time 5' and 3' non-coding regions are deleted. 
The PCR fragment was cloned as a BamHI-EcoRI fragment into the 
vector pBluescript II KS+ (Stratagene). The coding region was se- 
quenced by the enzymatic hain termination method [17] and was 
finally transferred as a BamHI-Spel fragment to the mammalian cell 
expression plasmid Zem219b [18] which carries a mouse metallothio- 
nein promoter for transcription of the inserted cDNA and the dihy- 
drofolate reductase cDNA under the control of an SV40 early pro- 
moter for use as a selectable marker. The resulting plasmid was 
designated pLN174. 
The y35D mutant was constructed by overlap extension using PCR 
[19]. Briefly, two PCR fragments were prepared with Pwo polyrnerase 
using the human cDNA [16] as a template and primers A+C (5' 
fragment) and B+D (3' fragment). The two fragments were purified 
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by agarose gel electrophoresis and overlapped by PCR using Pwo 
polymerase and primers A+B. The resulting PCR fragment was 
cloned into the vector pBluescript II KS+ as described above for 
the wild-type cDNA. The region between the BgllI and XbaI sites 
(base pairs 201 534 of the fVII coding sequence) was verified by 
sequencing and the internal BgllI-XbaI fragment was removed from 
the plasmid pLNI74 and replaced with the corresponding fragment 
from the mutant plasmid. The presence of the mutation in the final 
expression construct was verified by sequencing. The resulting expres- 
sion plasmid was designated pLN198. 
The 735Q and 735V mutants were constructed in a similar manner 
with primers A+E (735Q) and A+G (735V) for the 5' fragments and 
primers B+F (735Q) and B+H (735V) for the 3' fragments. Prepara- 
tion of fragments, overlapping, cloning into pBluescript II KS+ and 
preparation of the final expression construct were performed as de- 
scribed above for the T35D mutant. The resulting expression plasmids 
were designated pLN199 (735Q mutant) and pLN200 (735V mutant). 
DNA for transfection was prepared using the Qiagen maxiprep kit. 
2.3. Transfection 
The baby hamster kidney cell line BHK570 (ATCC CRL 1632) was 
transfected with the mutant fVIl expression plasmids (pLN198, 
pLNI99 and pLN200) using a modified calcium phosphate method 
[20]. Briefly, 2.5 × 105 cells were seeded on day 0 in a 6 cm Petri dish. 
On day 1, the medium (5 ml of Dulbecco-modified Eagle's medium 
containing 10% fetal bovine serum) was changed and the DNA mix- 
ture (500 tal containing 20 ~tg DNA, 0.12 M CaCI2, 0.82% NaCI, 0.6% 
HEPES, and 0.02% Na2HPO4) was added. Before incubation, 50 ~tl 
chloroquine (10 mM) was added to the dish. On day 2 the medium 
was changed and later the same day the cells were transferred to a T80 
culture flask. Selection pressure (1 I.tM methotrexate) was applied on 
day 3 and the cultures were incubated until clones were visible with 
the naked eye. The cultures were then transferred to T80 flasks for 
further culture and freezing. 
2.4. Expression and purification of mutant fV l l  
Pools of transfectants prepared as described above were seeded into 
two three-layer T175 culture flasks (Nunc) and allowed to grow to 
confluency in Dulbecco-modified Eagle's medium containing 10% fe- 
tal bovine serum. The medium was aspirated and replaced by 100 ml 
of the same medium containing 2% fetal bovine serum and 5 /.tg/ml 
vitamin K. The medium was harvested and fresh medium added after 
2 or 3 days of incubation. Medium was harvested 4 times from each 
pool of transfectants. 
Prior to purification, CaCl~ was added to the harvested media to a 
final concentration f 10 mM and pH was adjusted to 8.0. The mutant 
proteins were purified by affinity chromatography employing the 
monoclonal antibody F1A2 [14]. The F1A2-Sepharose column was 
equilibrated with 20 mM Tris, pH 8.0, containing 0.1 M NaCI and 
10 mM CaCI2, and washed with the same buffer after sample applica- 
tion. The proteins were eluted with the same buffer containing 10 mM 
EDTA instead of CaCI2. After purification, the concentrations of all 
mutants were determined in an ELISA. 
2.5. Activity assays 
The amidolytic activity was measured by mixing fVlIa (final con- 
centration 100 nM) with the chromogenic substrate S-2288 (Chromo- 
genix, final concentration 2 mM) in 50 mM HEPES, pH 7.5, contain- 
ing 0.1 M NaC1, 5 mM CaC12 and 1 mg/ml BSA. The mixture was 
incubated for 50 min at ambient emperature and the absorbance at 
405 nm was read every 10 min. 
The clotting activity was determined by adding various concentra- 
tions of fVIIa sample to fVII-deficient plasma and then mixing 50 Jal 
Table 1 
Kinetic and equilibrium constants for the interactions between solu- 
ble TF and fVIIa molecules ubstituted in position 35 
Complex k~ (× 105) kd ()< 10 -4) Kd (nM) 
(M ls -1)  (S I) 
fVIIa:TF 3.4 11 3.2 
y35D-fVIIa:TF 0.86 12 14 
y35Q°fVIIa :TF 0.44 8.5 19 
y35V-fVIIa:TF 0.015 9.8 650 
900 
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Fig. 1. Corrected sensorgrams for the interactions between the indi- 
cated variants of fVIIa and immobilized soluble TF. The analyte 
concentration was 100 nM. 
plasma with 50 Ixl relipidated TF (Innovin, Baxter, diluted 12.5-fold 
after dissolution prior to the assay) and 50 ~tl buffer (50 mM HEPES, 
pH 7.5, 0.1 M NaCI). This mixture was incubated at 37°C for 1 rain, 
clot formation was initiated by the addition of 50 Ixl buffer supple- 
mented with 20 mM CaC12 and the clotting time was recorded on an 
Amelung KC4A coagulometer. 
2.6. Tissue factor binding experiments 
The analyses were performed using a BIAcore instrument (Pharma- 
cia Biosensor) as described [21] with a few minor modifications: Sol- 
uble TF was coupled to the sensor chip at a level of 740 resonance 
units and 100 nM of the different fVIIa forms in 20 mM HEPES, pH 
7.5, containing 0.1 M NaC1, 5 mM CaCI2 and 0.02% Tween 80, was 
injected. The association and dissociation phases were 15 and 6 rain, 
respectively. Binding data was evaluated using a one-site model and 
the BIAevaluation 2.1 software. 
3. Results and discussion 
According to SDS-PAGE, all fVII species had been con- 
verted to two-chain fVIIa during the purification procedure. 
They displayed similar amidolytic activities (80-95% of wild- 
type) and similar specific procoagulant activities were meas- 
ured in a clot assay (data not shown). After this initial char- 
acterization we went on to specifically characterize the TF and 
Ca 2+ binding properties of the different fVIIa species. 
The binding of fVIIa to soluble TF was monitored using 
surface plasmon resonance, allowing both association and dis- 
sociation rates to be estimated. The recorded sensorgrams 
after background subtraction are shown in Fig. 1. The sensor- 
grams acquired with the isolated 735 and E35 forms of fVIIa 
were identical to that of fVIIa (which is a mixture of the two 
forms) and are omitted. Taking into account the molecular 
masses of fVIIa and soluble TF, the maximal response signal 
indicated that approx. 60% of the immobilized TF  molecules 
were able to bind fVIIa. Evaluation of the binding data re- 
vealed that the apparently slower association of the mutant  
forms of fVIIa with soluble TF indeed was solely due to 
decreased association rates, whereas the dissociation rates 
were similar for all fVIIa forms (Table 1). The association 
rate decreased in the order fVI Ia>y35D-fVI Ia>y35Q- 
fVIIa>y35V-fVIIa, with the big drop occurring between the 
two last mutants. The structure of the fVI Ia :TF complex re- 
veals no direct contr ibution of residue 35 to the interaction 
with TF [4] and apparently the two relatively conservative 
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Fig. 2. Ca2+-dependent binding of the various factor VIIa muteins 
to monoclonal antibodies directed against he Gla domain. The 
binding of wild-type factor VIIa (R), 735D-fVIIa (t3), 735Q-fVIIa 
(©) and y35V-fVIIa (zx) to F6A4 (A) and F1A2 (B) was measured 
at the indicated Ca 2+ concentrations. The data points represent the 
mean of duplicate xperiments. 
substitutions are reasonably tolerated. However, the T35V mu- 
tation may distort the a-helical environment of residue 35, 
perhaps influencing the presentation of Phe-31 and Phe-40 
[4], leading to a decreased rate of association. At present, 
we do not know why the impaired TF binding was not re- 
vealed in the clot assay. A comparison with a previous tudy 
of the kinetics of the binding of N-terminally truncated forms 
of fVIIa to soluble TF [21] generates two very interesting 
observations apart from the fact that both the mutations 
and truncations decreased the affinity for TF. Firstly, whereas 
truncations in the N-terminus of fVIIa cause an increased 
dissociation rate without affecting the association process 
the mutations at position 35 have the opposite effect. Sec- 
ondly, it appears as if T35V-fVIIa has a lower affinity for 
TF than does a fVIIa molecule lacking the first 44 amino 
acid residues, i.e. the entire Gla domain and hydrophobic 
stack. 
The recognition of wild-type and mutant fVIIa by two 
Ca2+-dependent monoclonal antibodies, F1A2 and F6A4, 
was investigated in order to characterize the Ca 2+ binding 
properties of the mutant proteins. Again, no difference was 
observed between the 735 and E35 forms of fVIIa (not 
shown). A lower apparent binding of F6A4 was observed 
for 735V-fVIIa. Residue 35 is either part of or in close proxi- 
mity of the epitope [14] and the lower response supports the 
assumption that the T35V mutation introduces structural 
changes that also may cause the decreased TF binding, The 
Ca 2+ dependencies of all fVIIa mutants for binding to F6A4 
were nevertheless imilar to that of the wild-type protein (Fig. 
2). In contrast, binding to F1A2, with its epitope in residues 
3-10 of fVIIa [22], required higher Ca 2÷ concentrations for 
the mutants and in particular for T35V-fVIIa. Thus, mutagen- 
esis of residue 35 appeared to affect the Ca2+-mediated induc- 
tion of structural order in the N-terminal part of the Gla 
domain. This part of the Gla domain is not involved in the 
contact with TF [4] and the suboptimal folding of this region 
of the T35V-fVIIa molecule at 5 mM Ca 2+ is presumably not 
what caused the reduced affinity for TF. In addition, the 
binding of T35V-fVIIa to TF in the BIAcore was the same 
at 5 and 10 mM Ca 2+ (not shown). It may, however, bear 
consequences on the ability to bind phospholipids. 
Our results, in agreement with data obtained for the two C- 
terminal Gla residues in factor IX, show that 7-carboxylation 
of Glu-35 in fVIIa appears to be of no functional importance 
and do not encourage fforts to optimize this modification 
during the mammalian cell production of recombinant vita- 
min K-dependent clotting factors. In contrast, mutations at 
position 35 in fVIIa, which is occupied by a Gla residue in 
plasma fVIIa and by Gla or Glu in recombinant fVIIa, affect 
the affinity for TF. Indeed, a 735V substitution results in low- 
er TF affinity than does removal of the entire Gla domain. 
The effect is caused solely by a decreased association rate. 
Conceivably, an improperly structured Gla domain, perhaps 
also with suboptimal relative orientations of the Gla and first 
epidermal growth factor-like domains, may obstruct he asso- 
ciation of fVIIa with TF. 
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